Sarcoidosis Versus Lymphoma?
Authors : Dal Lago L, Sarrand J, Woff E, Awada A, Vouche M, Pepersack T
Year : 2021
Journal : Eur J Case Rep Intern Med
Volume : 8
Pages : 002250
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
Authors : Lim B, Potter DA, Salkeni MA, Silverman P, Haddad TC, Forget F, Awada A, Canon JL, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Vincent S, Bahamon B, Galinsky KJ, Patel C, Neuwirth R, Leonard EJ, Diamond JR
Year : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 3329-3338
Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.
Authors : Franzoi MA, Saude Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E
Year : 2021
Journal : Breast
Volume : 57
Pages : 86-94
Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
Authors : Agostinetto E, Eiger D, Lambertini M, Ceppi M, Bruzzone M, Pondé N, Plummer C, Awada A, Santoro A, Piccart-Gebhart M, de Azambuja E
Year : 2021
Journal : Eur J Cancer
Volume : 148
Pages : 76-91
Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
Authors : Sabbah M, Krayem M, Najem A, Sales F, Miller W, Del Rincon S, Awada A, Ghanem GE, Journe F
Year : 2021
Journal : Mol Cancer Res
Volume : 19
Pages : 1221-1233
Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey.
Authors : Cufer T, Kosty M, Osterlund P, Jezdic S, Pyle D, Awada A, Close J, El-Saghir N, Lordick F, Rutkowski P, Tfayli A, Wildiers H
Year : 2021
Journal : ESMO Open
Volume : 6
Pages : 100219
The NHance<sup>®</sup> Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.
Authors : Aftimos P, Rolfo C, Rottey S, Barthélémy P, Borg C, Park K, Oh DY, Kim SW, De Jonge N, Hanssens V, Zwanenpoel K, Molthoff C, Vugts D, Dreier T, Verheesen P, van Dongen GAMS, Jacobs J, Van Rompaey L, Hultberg A, Michieli P, Pauwels P, Fung S, Thibault A, de Haard H, Leupin N, Awada A
Year : 2021
Journal : Biomedicines
Volume : 9
Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.
Authors : Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, DHondt L, Pierre P, Ghillemijn B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, Hendlisz A
Year : 2021
Journal : Cancer Med
Volume : 10
Pages : 4366-4374
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.
Authors : Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, Criscitiello C, Awada A, Loi S
Year : 2021
Journal : Expert Opin Biol Ther
Volume : 21
Pages : 945-962
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
Authors : van Bussel MTJ, Awada A, de Jonge MJA, Mau-Sørensen M, Nielsen D, Schöffski P, Verheul HMW, Sarholz B, Berghoff K, El Bawab S, Kuipers M, Damstrup L, Diaz-Padilla I, Schellens JHM
Year : 2021
Journal : Br J Cancer
Volume : 124
Pages : 728-735
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Authors : Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP
Year : 2021
Journal : Target Oncol
Volume : 16
Pages : 47-57
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Authors : Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E
Year : 2021
Journal : Target Oncol
Volume : 16
Pages : 37-46
Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer.
Authors : Tolaney SM, Sahebjam S, Rhun EL, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK
Year : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 1582
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.
Authors : Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jøssang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, Brunsvig P, Nicolaisen B, Saunders A, Patel H, Galon J, Hermitte F, Camilio KA, Mauseth B, Sundvold V, Sveinbjørnsson B, Rekdal Ø
Year : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 2755-2763
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.
Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 125
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Authors : Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J
Year : 2020
Journal : Lung Cancer
Volume : 150
Pages : 90-96
Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. <i>
Authors : Krayem M, Aftimos P, Najem A, Hooven TVD, Berg AVD, Hovestad-Bijl L, Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem G
Year : 2020
Journal : Cancers (Basel)
Volume : 12
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Authors : Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Garcia-Estevez L, Hart L, Awada A, Zamagni C, Morris PG, Schwartzberg L, Chan S, Gucalp A, Biganzoli L, Steinberg J, Sica L, Trudeau M, Markova D, Tarazi J, Zhu Z, OBrien T, Kelly CM, Winer E, Yardley DA
Year : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 6149-6157
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms.
Authors : Saini KS, de Las Heras B, Plummer R, Moreno V, Romano M, de Castro J, Aftimos P, Fredriksson J, Bhattacharyya GS, Olivo MS, Schiavon G, Punie K, Garcia-Foncillas J, Rogata E, Pfeiffer R, Orbegoso C, Morrison K, Curigliano G, Chin L, Saini ML, Rekdal Ø, Anderson S, Cortes J, Leone M, Dancey J, Twelves C, Awada A
Year : 2020
Journal : JCO Glob Oncol
Volume : 6
Pages : 1357-1362
Oncological care organisation during COVID-19 outbreak.
Authors : Onesti CE, Rugo HS, Generali D, Peeters M, Zaman K, Wildiers H, Harbeck N, Martin M, Cristofanilli M, Cortes J, Tjan-Heijnen V, Hurvitz SA, Berchem G, Tagliamento M, Campone M, Bartsch R, De Placido S, Puglisi F, Rottey S, Müller V, Ruhstaller T, Machiels JP, Conte P, Awada A, Jerusalem G
Year : 2020
Journal : ESMO Open
Volume : 5